Activity of Dasatinib, a Dual SRC/ABL Kinase Inhibitor, and IPI-504, a Heat Shock Protein 90 Inhibitor, Against Gastrointestinal Stromal Tumor-Associated PDGFRAD842V Mutation

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-08-0533
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Antitumor Activity and Molecular Effects of the Novel Heat Shock Protein 90 Inhibitor, IPI-504, in Pancreatic Cancer

Molecular Cancer Therapeutics
Cancer ResearchOncology
2008English

The Heat Shock Protein 90 Inhibitor IPI-504 Induces Apoptosis of AKT-dependent Diffuse Large B-Cell Lymphomas

British Journal of Haematology
Hematology
2009English

Preclinical Antitumor Activity of SST0116CL1: A Novel Heat Shock Protein 90 Inhibitor

International Journal of Oncology
Cancer ResearchOncology
2014English

Scalable and Impurity-Free Process for Dasatinib: SRC and BCR-Abl Inhibitor

Asian Journal of Chemistry
Chemistry
2018English

Abrogation of Heat Shock Protein 70 Induction as a Strategy to Increase Antileukemia Activity of Heat Shock Protein 90 Inhibitor 17-Allylamino-Demethoxy Geldanamycin

Cancer Research
Cancer ResearchOncology
2005English

Potent Activity of a Novel Dimeric Heat Shock Protein 90 Inhibitor Against Head and Neck Squamous Cell Carcinoma in Vitro and in Vivo

Clinical Cancer Research
Cancer ResearchOncology
2005English

In Vitro and in Vivo Activity of SKI-606, a Novel SRC-Abl Inhibitor, Against Imatinib-Resistant BCR-Abl+ Neoplastic Cells

Cancer Research
Cancer ResearchOncology
2006English

Evaluation of the Efficacy of Dasatinib, a SRC/Abl Inhibitor, in Colorectal Cancer Cell Lines and Explant Mouse Model

PLoS ONE
Multidisciplinary
2017English

The Heat Shock Protein 90 Inhibitor, (-)-Epigallocatechin Gallate, Has Anticancer Activity in a Novel Human Prostate Cancer Progression Model

Cancer Prevention Research
MedicineCancer ResearchOncology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy